Friday, August 04, 2023
GENIXUS, a pharmaceutical company specializing in acute and critical care medicines, has made a significant move by expediting the development and launch of their latest product, Rocuronium Bromide Injection. This decision comes as a response to the recent natural disaster that affected Pfizer's manufacturing site in Rocky Mount, NC. Due to the anticipated impact on the sterile injectables market resulting from this event, GENIXUS took proactive steps to introduce the product within their KinetiX syringe platform.
Our thoughts go out to those impacted by the natural disaster at Rocky Mount," expressed Kendall Foster, the CEO of GENIXUS. "We understand the severity of the situation and the crucial need for medications in the market. GENIXUS is committed to taking rapid action to address these challenges and ensure patients have access to the medications they require
KinetiX Rocuronium Bromide Injection incorporates several key attributes intrinsic to the KinetiX platform,Easy-to-read labeling and a color-coded plunger rod for quick identification.Designed to be compatible with auto-dispensing cabinets (ADC), allowing convenient access near the delivery site.Utilizes RFID technology in conjunction with KitCheck® for efficient kit and tray management.Available in 5mL and 10mL Ready-to-Administer (RTA) syringes, providing flexibility and minimizing wastage.Constructed with a durable polymer syringe, eliminating the risks associated with glass.Ensures a 3-month beyond-use date (BUD) from the launch date, ensuring the product's efficacy and quality.
GENIXUS' Chief Commercial Officer (CCO), Seth Coombs, has expressed the company's dedication to hastening the launch of Rocuronium Bromide Injection in response to the ongoing and expected shortages in the US market. Coombs stated, "GENIXUS is fully committed to supporting patient care during this critical time. Our decision to accelerate the development and market entry of Rocuronium Bromide Injection showcases our dedication to ensuring the availability of essential medications for patients across the country."
KinetiX Rocuronium Bromide Injection is the second product in the syringe platform, following the earlier launch of repackaged Propofol 10mL & 20mL Ready-to-Administer (RTA) syringes earlier this year by GENIXUS.
